{"product_id":"generic-venetoclax-vecladx","title":"VECLADX (Venetoclax)","description":"Venetoclax  is a medication used to treat adults with chronic lymphocytic leukemia(CLL), small lymphocytic lymphoma(SLL), or acute myeloid leukemia(AML).\r\n\u003ch3\u003eChronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma\u003c\/h3\u003e\r\nIndicated for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)\r\n\u003ch4\u003eDose ramp-up phase\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eAdminister dose according to a weekly ramp-up schedule over 5 weeks to the recommended daily dose of 400 mg\u003c\/li\u003e\r\n \t\u003cli\u003eRamp-up dosing schedule designed to gradually reduce tumor burden and decrease risk of tumor lysis syndrome\u003c\/li\u003e\r\n \t\u003cli\u003eWeek 1: 20 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eWeek 2: 50 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eWeek 3: 100 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eWeek 4: 200 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eWeek 5 and beyond: 400 mg PO qDay\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eMonotherapy\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e400 mg PO qDay after completing the 5-week dose ramp-up schedule\u003c\/li\u003e\r\n \t\u003cli\u003eContinue until disease progression or unacceptable toxicity\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eCombination with obinutuzumab\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eCycle 1\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eDay 1: Obinutuzumab 100 mg IV\u003c\/li\u003e\r\n \t\u003cli\u003eDay 2: Obinutuzumab 900 mg IV\u003c\/li\u003e\r\n \t\u003cli\u003eDays 8 and 15: Obinutuzumab 1000 mg IV\u003c\/li\u003e\r\n \t\u003cli\u003eDay 22: Start venetoclax according to 5-week ramp up schedule\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eCycle 2\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eDay 1: Obinutuzumab 1000 mg IV\u003c\/li\u003e\r\n \t\u003cli\u003eDay 28: After completing the ramp-up phase on Cycle 2 Day 28, continue venetoclax 400 mg qDay from Cycle 3 Day 1 until Cycle 12 Day 28\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eCycles 3-6\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eDay 1: Obinutuzumab 1000 mg IV\u003c\/li\u003e\r\n \t\u003cli\u003eDays 1-28: Continue venetoclax 400 mg PO qDay\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eCycles 7-12\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eDays 1-28: Continue venetoclax 400 mg PO qDay\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eCombination with rituximab\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eVenetoclax\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eComplete 5-week ramp-up dosing to reach 400 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eContinue venetoclax 400 mg PO qDay for 24 months from Cycle 1 Day 1 of rituximab\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eRituximab\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eInitiate 375 mg\/m² IV after patient has received venetoclax 400 mg\/day x 7 days (ie, this will be Day 1 of Cycle 1)\u003c\/li\u003e\r\n \t\u003cli\u003e500 mg\/m² IV on Day 1 for Cycles 2-6\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eAcute Myeloid Leukemia\u003c\/h3\u003e\r\nIndicated in combination with azacitidine or decitabine or low-dose cytarabine for treatment in adults (≥75 years) who are newly-diagnosed acute myeloid leukemia (AML) or who have comorbidities that preclude use of intensive induction chemotherapy\r\n\r\nVenetoclax dosing depends on the combination agent\r\n\u003ch4\u003eDose ramp-up phase\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eDay 1: 100 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eDay 2: 200 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eDay 3: 400 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eDay 4 and beyond (in combination with decitabine or azacitidine): 400 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eDay 4 and beyond (in combination with low-dose cytarabine): 600 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eIn combination with decitabine, azacitidine, or low-dose cytarabine: Continue until disease progression or unacceptable toxicity\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nRefer to prescribing information for azacitidine, decitabine, or cytarabine for additionaldosing information","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797948854315,"sku":"RL1020230315580","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-06-1962.jpg?v=1787022124","url":"https:\/\/xomeds.com\/products\/generic-venetoclax-vecladx","provider":"XOMEDS","version":"1.0","type":"link"}